Skip to main
ARGX

argenx (ARGX) Stock Forecast & Price Target

argenx (ARGX) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 41%
Buy 53%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

Argenx has experienced significant topline growth, with Q1 2025 revenue reaching $790 million, representing a 98% year-over-year increase, and Q2 2025 revenue of $949 million, reflecting a 97% year-over-year increase, driven primarily by the adoption of its pre-filled syringe format and expanded use in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company's innovative approach has been validated by promising clinical results, with phase Ib trials of ARGX-119 demonstrating clinically meaningful improvements in key measures, further positioning the company for a registrational Phase III trial in 2026. Additionally, the focus on label expansion opportunities in seronegative and pediatric forms of MG, along with increased prescriber engagement, suggests a robust growth trajectory supported by strong market demand for its therapies.

Bears say

Argenx faces several significant risks that contribute to a negative outlook on its stock, notably the potential for lower-than-anticipated growth in sales of its lead product, Vyvgart, and the possibility of unforeseen safety signals emerging during ongoing clinical trials. Additional factors include the threat of increased competition in the biopharmaceutical market, as well as broader macroeconomic challenges such as foreign exchange fluctuations, inflation, and shipping-related issues. Furthermore, the company's reliance on the successful penetration of new target populations for Vyvgart and its ongoing pipeline development raises concerns about the feasibility of achieving its projected market share, particularly in niche therapeutic areas.

argenx (ARGX) has been analyzed by 17 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 53% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of argenx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About argenx (ARGX) Forecast

Analysts have given argenx (ARGX) a Buy based on their latest research and market trends.

According to 17 analysts, argenx (ARGX) has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $996.82, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $996.82, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

argenx (ARGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.